A lambda clone with numb feet, swollen legs and painful breasts
Where to look
The acronym names the findings; 1, 2 and 3 close the diagnosis.
Ask at every MGUS visit
2. Swollen legs or belly, fluid on a chest film?
3. Platelets or hemoglobin drifting up rather than down?
4. Libido, breasts, darker or thicker skin, new body hair?
The myeloma screen is negative by design.Small clone; high platelets or hemoglobin in half; creatinine 1.5 or above in only 6%; SPEP positive in 24 to 54%, immunofixation in 85% (Dispenzieri 2019, 2026).
Not amyloid
Both are lambda. Nerve conduction and the cardiac markers pick the workup.If the M-protein was never sent, it was never excluded.
Decide in clinic
Ask the man with numb feet and an M-spike about his libido and his breasts.
Sources
Retrieved from PubMed, read on Oct 19, 2026; every figure re-checked against the primary text the same day.
- Dispenzieri A. POEMS syndrome: 2026 update on diagnosis, risk-stratification, and management. Am J Hematol 2026. doi:10.1002/ajh.70438
- Dispenzieri A. POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019. doi:10.1002/ajh.25495
- D'Souza A, Hayman SR, Buadi F, et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood 2011. doi:10.1182/blood-2011-06-362392
- D'Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome. Blood 2012. doi:10.1182/blood-2012-04-423178
- Humeniuk MS, Gertz MA, Lacy MQ, et al. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood 2013. doi:10.1182/blood-2013-03-487025
- Li J, Zhang W, Jiao L, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood 2011. doi:10.1182/blood-2010-12-328112
- Lee K, Kourelis T, Tschautscher M, et al. Capillary leak phenotype as a major cause of death in patients with POEMS syndrome. Leukemia 2025. doi:10.1038/s41375-024-02489-z
PSA 340 after six months of nothing
The fork
Document the six months as a lapse.SWOG 9346: intermittent ADT in metastatic disease, median survival 5.1 vs 5.8 years, HR 1.10, non-inferiority not shown (Hussain 2013).
Decide in clinic
2Testosterone 200
3Testosterone under 50
Progression within 12 months on the first inhibitor: cabazitaxel beats a second one (CARD).
Sources
Retrieved from PubMed, read on Oct 20, 2026; every figure re-checked against the primary text the same day.
- Scher HI, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016. doi:10.1200/JCO.2015.64.2702
- Nascimento B, et al. Testosterone recovery after androgen deprivation therapy. J Sex Med 2025. doi:10.1093/jsxmed/qdaf164
- Klotz L, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008. doi:10.1111/j.1464-410X.2008.08183.x
- Shore ND, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer (HERO). N Engl J Med 2020. doi:10.1056/NEJMoa2004325
- Smith MR, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer (ARASENS). N Engl J Med 2022. doi:10.1056/NEJMoa2119115
- Fizazi K, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1). Lancet 2022. doi:10.1016/S0140-6736(22)00367-1
- Armstrong AJ, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019. doi:10.1200/JCO.19.00799
- Armstrong AJ, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer (ARCHES final analysis). J Clin Oncol 2022. doi:10.1200/JCO.22.00193
- Smith MR, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009. doi:10.1056/NEJMoa0809003
- Hussain M, et al. Intermittent versus continuous androgen deprivation in prostate cancer (SWOG 9346). N Engl J Med 2013. doi:10.1056/NEJMoa1212299
- Patchell RA, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer. Lancet 2005. doi:10.1016/S0140-6736(05)66954-1
- Fizazi K, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer. Lancet 2011. doi:10.1016/S0140-6736(10)62344-6
- Saad F, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel final analysis). Lancet Oncol 2023. doi:10.1016/S1470-2045(23)00382-0
- Agarwal N, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2). Lancet 2023. doi:10.1016/S0140-6736(23)01055-3
- de Wit R, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer (CARD). N Engl J Med 2019. doi:10.1056/NEJMoa1911206
- Sartor O, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION). N Engl J Med 2021. doi:10.1056/NEJMoa2107322
- Eisenberger M, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer (PROSELICA). J Clin Oncol 2017. doi:10.1200/JCO.2016.72.1076
- Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer (ALSYMPCA). N Engl J Med 2013. doi:10.1056/NEJMoa1213755
Abiraterone and the three lutamides
Concepts first
Where each drug acts
The trials that put each drug on the shelf
Three settings, three columns; on a phone, slide the table sideways.
| Drug | Non-metastatic CRPC on ADT, testosterone under 50, PSA rising, nothing on CT and bone scan | Hormone-sensitive metastatic | Castration-resistant metastatic |
|---|---|---|---|
| Abiraterone 1,000 mg + prednisone | no trial | LATITUDE (high risk): OS 53.3 vs 36.5 mo, HR 0.66 STAMPEDE arm G: OS HR 0.61 in metastatic patients PEACE-1 (with docetaxel): OS HR 0.82; 0.75 in the docetaxel group | COU-AA-302 (before chemo): OS 34.7 vs 30.3 mo, HR 0.81 COU-AA-301 (after docetaxel): OS 15.8 vs 11.2 mo, HR 0.74 |
| Enzalutamide 160 mg daily | PROSPER: MFS 36.6 vs 14.7 mo, HR 0.29; OS HR 0.73 | ARCHES: rPFS HR 0.39; OS HR 0.66 ENZAMET: OS HR 0.70 (5 years) | PREVAIL (before chemo): OS 35.3 vs 31.3 mo, HR 0.77 AFFIRM (after docetaxel): OS 18.4 vs 13.6 mo, HR 0.63 |
| Apalutamide 240 mg daily | SPARTAN: MFS 40.5 vs 16.2 mo, HR 0.28; OS HR 0.78 | TITAN: OS HR 0.65 (final); rPFS HR 0.48 | not approved |
| Darolutamide 600 mg twice daily | ARAMIS: MFS 40.4 vs 18.4 mo, HR 0.41; OS HR 0.69 | ARASENS (with docetaxel): OS HR 0.68 ARANOTE (without docetaxel): rPFS HR 0.54 | not approved |
Every box is a comparison against ADT, or ADT plus docetaxel, alone. No phase 3 has put one of the four against another.All placebo-controlled except STAMPEDE, PEACE-1 and ENZAMET, which were open label (ENZAMET against a first-generation antiandrogen). The one randomized sequencing study, phase 2, favored abiraterone first and enzalutamide second (Khalaf 2019). MFS: metastasis-free survival. OS: overall survival. rPFS: radiographic progression-free survival. HR: hazard ratio.
Choose the pill
A second lutamide after the first fails is a change of brand.After docetaxel and one inhibitor, cabazitaxel beat the second inhibitor (CARD, de Wit 2019).
Sources
Retrieved from PubMed, read on Oct 20, 2026.
- Fizazi K, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis. Lancet Oncol 2019. doi:10.1016/S1470-2045(19)30082-8
- James ND, et al. Abiraterone for prostate cancer not previously treated with hormone therapy (STAMPEDE). N Engl J Med 2017. doi:10.1056/NEJMoa1702900
- Ryan CJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis. Lancet Oncol 2015. doi:10.1016/S1470-2045(14)71205-7
- Fizazi K, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012. doi:10.1016/S1470-2045(12)70379-0
- Hussain M, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer (PROSPER). N Engl J Med 2018. doi:10.1056/NEJMoa1800536
- Armstrong AJ, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer (ARCHES). J Clin Oncol 2022. doi:10.1200/JCO.22.00193
- Sweeney CJ, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol 2023. doi:10.1016/S1470-2045(23)00063-3
- Beer TM, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 2017. doi:10.1016/j.eururo.2016.07.032
- Scher HI, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy (AFFIRM). N Engl J Med 2012. doi:10.1056/NEJMoa1207506
- Smith MR, et al. Apalutamide and overall survival in prostate cancer (SPARTAN final analysis). Eur Urol 2021. doi:10.1016/j.eururo.2020.08.011
- Chi KN, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 2021. doi:10.1200/JCO.20.03488
- Fizazi K, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide (ARAMIS). N Engl J Med 2020. doi:10.1056/NEJMoa2001342
- Smith MR, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer (ARASENS). N Engl J Med 2022. doi:10.1056/NEJMoa2119115
- Saad F, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol 2024. doi:10.1200/JCO-24-01798
- Fizazi K, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1). Lancet 2022. doi:10.1016/S0140-6736(22)00367-1
- Sternberg CN, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer (PROSPER). N Engl J Med 2020. doi:10.1056/NEJMoa2003892
- Armstrong AJ, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019. doi:10.1200/JCO.19.00799
- Smith MR, et al. Apalutamide treatment and metastasis-free survival in prostate cancer (SPARTAN). N Engl J Med 2018. doi:10.1056/NEJMoa1715546
- Chi KN, et al. Apalutamide for metastatic, castration-sensitive prostate cancer (TITAN). N Engl J Med 2019. doi:10.1056/NEJMoa1903307
- Fizazi K, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer (ARAMIS). N Engl J Med 2019. doi:10.1056/NEJMoa1815671
- Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009. doi:10.1126/science.1168175
- Moilanen AM, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 2015. doi:10.1038/srep12007
- Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate. J Clin Oncol 2008. doi:10.1200/JCO.2007.15.9749
- Khalaf DJ, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 2019. doi:10.1016/S1470-2045(19)30688-6
- de Wit R, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer (CARD). N Engl J Med 2019. doi:10.1056/NEJMoa1911206